Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Work at Aston University has led to the identification of tissue transglutaminase (TGM2) inhibitors potentially useful for the treatment of fibrosis, thrombosis, cancer, AIDS, inflammation, transplant ...

Tyligand Bioscience Ltd. has prepared and tested tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Researchers leverage artificial intelligence and machine learning techniques to investigate which among thousands of ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...